Title

BRAF mutations increase response to MEK inhibition

Document Type

Article

Department

Ophthalmology

Abstract

Tumours with BRAF mutations, irrespective of site of origin, are sensitive to mitogen-activated protein kinase kinase (MEK) inhibitors, say researchers in Nature

Publication

Lancet Oncology